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Inhibition of allogeneic inflammatory responses
by the Ribonucleotide Reductase Inhibitors, Didox
and Trimidox
Mohammed S Inayat1, Ismail S El-Amouri1, Mohammad Bani-Ahmad1, Howard L Elford2, Vincent S Gallicchio3,
Oliver R Oakley1*
Abstract
Background: Graft-versus-host disease is the single most important obstacle facing successful allogeneic stem cell
transplantation (SCT). Even with current immunosuppressive therapies, morbidity and mortality rates are high.
Current therapies including cyclosporine A (CyA) and related compounds target IL-2 signaling. However, although
these compounds offer great benefit, they are also associated with multiple toxicities. Therefore, new compounds
with a greater efficacy and reduced toxicity are needed to enable us to overcome this hurdle.
Methods: The allogeneic mixed lymphocyte reaction (MLR) is a unique ex vivo method to study a drug’s action on
the initial events resulting in T-cell activation and proliferation, synonymous to the initial stages of tissue and organ
destruction by T-cell responses in organ rejection and Graft-versus-host disease. Using this approach, we examined
the effectiveness of two ribonucleotide reductase inhibitors (RRI), Didox and Trimidox, to inhibit T-cell activation
and proliferation.
Results: The compounds caused a marked reduction in the proliferative responses of T-cells, which is also
accompanied by decreased secretion of cytokines IL-6, IFN-g, TNF-a, IL-2, IL-13, IL-10 and IL-4.
Conclusions: In conclusion, these data provide critical information to justify further investigation into the potential
use of these compounds post allogeneic bone marrow transplantation to alleviate graft-versus-host disease thereby
achieving better outcomes.
Introduction
Graft-versus-host disease remains one the most frequent
causes of morbidity in bone marrow transplantation. Cur-
rent therapies address one of the six main immunosup-
pressive strategies in organ transplantation: proliferation,
depletion, cytokines, costimulation, ischemia-reperfusion
injury, and tolerance [1]. Many of these therapies are only
successful in reducing acute organ rejection and do noth-
ing for the long term survival of the graft, whilst others are
associated with non-favorable side effects. The adverse
effects of current treatments include hypertension, osteo-
porosis, hyperglycemia (steroids); hepatic dysfunction,
thrombocytopenia, marrow suppression (azathioprine);
limb paralysis and convulsion (cyclosporine). Therefore,
the search continues for new therapeutic modalities that
enable the long term survival of grafted tissue within the
host with minimal side effects. To achieve this objective
has led to the alternative therapeutic approach targeting
key enzymes that control cell proliferation such as ribonu-
cleotide reductase. The rate limiting step in DNA synth-
esis is the production of deoxynucleoside triphosphates
(dNTPs) catalyzed by ribonucleotide reductase. Inhibition
of ribonucleotide reductase results in reduced DNA synth-
esis and cell cycle arrest [2]. This has made ribonucleotide
reductase inhibitors potentially attractive clinical agents
for the treatment of numerous conditions characterized by
excessive cell proliferation or inappropriate immune acti-
vation such as myeloproliferative disorders [3,4], psoriasis
[5], sickle cell anemia [6,7], and HIV [8].* Correspondence: oroakl1@uky.edu1Department of Clinical Sciences, University of Kentucky, Lexington, KY
40536, USA
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Didox and Trimidox are polyhydroxyphenyl hydroxa-
mic acid derivatives that are more potent inhibitors of
ribonucleotide reductase than the current clinical com-
pound, hydroxyurea (HU), which targets ribonucleotide
reductase [9,10]. They have been evaluated in several
animal models to compare their actions to that of HU.
These studies evaluate their use in animal models of
HIV [9], sickle cell disease [11], and several malignan-
cies [12] and have shown that these compounds have
greater therapeutic effectiveness and lower toxicity than
HU. Given the potent efficacy and low toxicity of Didox
and Trimidox in animal models, and the potential utility
of ribonucleotide reductase inhibitors as cytostatic
agents that may influence immune cell activation, we
investigated the anti-inflammatory ability of Didox and
Trimidox as a therapeutic approach to improve trans-
plant success. Our findings clearly demonstrate that
these compounds inhibit both T-cell proliferation and
cytokine production following anti-CD3ε stimulation as
well as in allogeneic mixed lymphocyte reactions. Not
only does this have implications for monotherapy, but it
has been previously shown that ribonucleotide reductase
inhibitors, specifically HU are able to potentiate other
drugs in a combination drug therapy [13]. The studies
reported here should promote further examination into
the use of Didox and Trimidox as potentiators of cur-
rent therapies, thereby reducing the required dose level
and associated side effects to achieve similar efficacy.
Materials and methods
Drug Treatment
Didox and Trimidox were synthesized and kindly pro-
vided by Dr Howard Elford, Molecules for Health (Rich-
mond, VA). All of the compounds were dissolved in
0.9% sterile saline solution then filtered through a
0.45 μm syringe top filter and stored at 4°C in the dark
for a maximum of 1 week.
Mice
Female C57BL6, BALB/c mice aged 6-8 weeks were pur-
chased from Harlan (Indianapolis, ID) and B10.D2 mice
were obtained from The Jackson Laboratories (Bar Har-
bor, ME). They were housed in micro-isolator cages in
temperature and humidity controlled environment and
were given Purina Lab Chow and water ad libitum.
Mice were quarantined for one week post arrival as per
University of Kentucky Division of Lab Animal Research
(DLAR) Standard Operating Procedures (SOP). All pro-
tocols and procedures used were approved by the Uni-
versity of Kentucky Institutional Animal Care and Use
Committee (IACUC) prior to initiation of research.
Cell lines
CCL-1972 mouse embryonic fibroblast (MEF) cells were
obtained from the American Type Tissue Culture Col-
lection (ATCC: Manassas, VA). They were propagated
in T75 canted neck culture flasks in Dulbecco’s Modi-
fied Eagles Medium (DMEM: Gibco BRL, Grand Island,
N.Y) supplemented with 10% fetal bovine serum (Sigma
Chemical Co, St. Louis, USA) and 1% Penicillin/Strepto-
mycin (Gibco BRL. 10,000 units per ml penicillin
+10,000 mg/ml streptomycin sulphate in 0.85% saline),
and maintained in an incubator (Queue: Cell culture
incubator) at 37°C and 5% carbon dioxide humidified
atmosphere.
T-cell Isolation
Mice were killed and the spleens were aseptically
excised and placed into a Petri dish containing 3 ml of
2 mg/ml Collagenase I (Gibco), cut into small pieces
and incubated for 60 minutes at 37°C. The whole spleen
suspension was then gently pushed through a 70 μm
nylon filter (Falcon, BD, Franklin Lakes, NJ). The filtrate
was washed twice in 15 ml of HBSS (Gibco), then resus-
pended in 400 μl of degassed MACS buffer (PBS pH
7.2, 2 mM EDTA and 0.5% BSA) per spleen. T-cells
were separated using MACS LS separation columns as
per manufacturer’s instructions. Magnetic Labeling: (Pan
T-Cell Isolation Kit, Miltenyi Biotec Inc, Auburn, CA)
100 μl of Biotin-antibody cocktail was added per spleen,
mixed and incubated for 10 minutes at 4°C. Then,
300 μl of buffer and 200 μl of anti-biotin Microbeads
were added and incubated for a further 15 minutes at
4°C. The cells were then washed in 5 ml buffer at
1200 RPM, 4°C for 10 minutes. Finally, the pellet was
resuspended in 1 ml of buffer. Magnetic Separation: The
LS column was prepared by pre-rinsing with 3 ml of
buffer. The labeled suspension was then gently added to
the column and the unlabelled effluent collected fol-
lowed by 4 washes of 3 ml each to increase T-cell yield.
T-Cell proliferation assay
Cell proliferation and viability were determined using
WST-1 colorimetric assay system which is based on the
cleavage of tetrazolium salt by mitochondrial dehydro-
genase in viable cells (Roche Applied Sciences, Penz-
berg, Germany). A concentration of 5×104 cells per well
was added to a 96 well flat bottom plate (Costar, Corn-
ing, NY) pre-coated with immobilized anti-CD3ε (with
or without drug treatment) and incubated at 37°C and
5% CO2. Proliferation was determined as per the manu-
facturer’s instructions at 24, 48, 72 and 96 hours post
treatment.
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Cytokine Analysis
T-cells (1×105 per well) were incubated at 37°C and 5%
CO2 in 96-well plates (Costar, Corning, NY) coated with
anti-CD3ε monoclonal antibodies (eBioscience, San
Diego, CA). Culture supernatants were taken at 24 and
48 hour time points; the supernatants were spun free of
cells and aliquots were frozen at -80°C. Levels of cyto-
kine secretion (IL-2, IL-4, IL-6, IL-10, IL-12p70, IL-13,
IFN-g and TNF-a) were analyzed with the Searchlight
multiplex assay system (Pierce Biotechnology Inc,
Woburn, MA). Briefly, Custom 96 well culture plates
(Costar) were manufactured which contained target cap-
ture antibodies as indicated above. 50 μl of the superna-
tant was then added to each well for 1 hour, followed
by three washes and the addition of biotinylated second-
ary antibodies for 30 minutes. The wells were then
washed again and streptavidin-horseradish peroxidase
(SA-HRP) conjugate was added followed by the addition
of SuperSignal® ELISA Femto chemiluminescent sub-
strate. The luminescence was then detected and ana-
lyzed using a cooled charge-coupled device imager
(Pierce Biotechnology Inc).
Mixed Lymphocyte Reaction
T-cell depleted stimulator cells were obtained from sple-
nocytes from BALB/c mice by magnetic bead purifica-
tion (Miltenyi Biotec). The cells were collected in RPMI
1640 growth media (Gibco) supplemented with 10%
fetal bovine serum (Sigma), 50 μM 2-mercaptoethanol
(Sigma) and 1% penicillin streptomycin (Gibco) and irra-
diated with 3000 rads of g-radiation form a Cs-137
source.
Responder T-cells were isolated as previously
described (Miltenyi Biotec) from C57BL6 (Major antigen
mismatch) mice and B10.D2 (Minor antigen mismatch)
mouse strains. A total of 2 × 105 responder cells were
combined with 4 × 105 stimulator cells per well in 96
well flat bottom plates (Costar) and incubated at 37°C
and 5% CO2. T-cell culture media, RPMI 1640 (Gibco)
containing 10% fetal bovine serum (Sigma), 50 μM
2-mercaptoethanol (Sigma) and 1% penicillin streptomy-
cin (Gibco) was supplemented with either Didox or
Trimidox from 25 μM-100 μM or PBS and the MLRs
were analyzed in triplicate on day 6.
Statistical analysis
When applicable, results were subjected to statistical
analysis. Data were analyzed and plotted using Sigma-
Plot version 10.0 (Systat software Inc., Chicago, IL). On
graphs, error bars represent one standard error (± SE)
around the average of data per group. To determine the
statistical significance between groups, ANOVA was
performed followed by post-hoc analysis using Bonfer-
roni method. Data that failed normality testing was
normalized using log transformation. p values < 0.05
were considered significant.
Results
Didox and Trimidox inhibit T-cell proliferation in CD3ε
stimulated cultures
To determine the influence of Didox and Trimidox on
T-cell proliferation, we first studied the effects of the
compounds on T-cell proliferation in response to CD3ε
stimulation. Untreated control cultures did not show
detectable proliferation throughout the experiments.
Following stimulation, proliferation was detected in sti-
mulated control cultures at 48 hours. The control cul-
tures continued to proliferate rapidly until the last time
point assayed at 96 hours post stimulation (Figure 1).
Didox (Figure 1A) treatment at the lowest concentration
(25 μM) reduced T-cell proliferation by approximately
90% at 96 hours post stimulation, and proliferation was
undetectable when treated with 50 μM. Trimidox (Fig-
ure 2B) at 25 μM inhibited proliferation by approxi-
mately 65% compared to stimulated control at 96 hours
post stimulation and completely blocked proliferation at
50 μM concentration.
Suppression of T-cell proliferation by Didox and Trimidox
is not due to the cytotoxic effects of the treatment
To determine if the lack of proliferation was a result of
the toxicity of the compounds, we studied the effects of
drug treatment on cell viability. In the proliferation stu-
dies, we observed that 50 μM of Didox or Trimidox was
sufficient to completely block T-cell proliferation (Figure
1). Figure 2A. shows cell viability of B10.D2 and C57BL6
T-cells in response to Didox treatment. The results indi-
cate that C57BL6 cells are more tolerant to the treat-
ment than B10.D2 cells. Even so, Didox treatment only
reduced cell viability in the B10.D2 cells by 20% at 100
μM. The C57BL6 cells were more tolerant to the com-
pound and had a minimal (5%) reduction in cell viability
at the highest concentration used (100 μM). Figure 2B
shows cell viability in response to Trimidox treatment.
We observed an approximate 15% reduction in cell via-
bility at the minimal effective dose (25 μM). Cell viabi-
lity in both B10.D2 and C57BL6 was decreased to less
than 50% when cells were exposed to 100 μM
concentrations.
Suppression of anti CD3ε induced cytokine production in
T-cell cultures by Didox and Trimidox
We next studied the effects of Didox and Trimidox on
cytokine production. As mentioned previously, many
current therapies target cytokine signaling or produc-
tion, in particular the CyA derivatives inhibit signaling
through IL-2. T-cell cultures stimulated with anti-
CD3ε were tested for cytokine activity using the
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Searchlight multiplex assay at 24 and 48 hours post
stimulation. We tested both B10.D2 (Figure 3A) and
C57BL6 (Figure 3B) cells independently. As expected,
the unstimulated (NC) (no anti-CD3ε treatment) cells
showed minimal cytokine production. However, in as
little as 24 hours, both C57BL6 and B10.D2 cells
responded to anti-CD3ε (AC) by increasing secretion
of IFN-g, IL-2 and IL-6. In contrast, cells treated
simultaneously with Didox and anti-CD3ε demon-
strated a dose response inhibition of cytokine produc-
tion at 24 or 48 hours post stimulation compared to
the activated controls (AC) (p < 0.02).
Figure 1 Inhibition of proliferation of T-cell obtained from B10.D2 mice spleens. Briefly, 5 × 104 T-cells per well were purified and seeded
in 96 well sterile plates pre-coated with PBS or anti CD3ε antibodies (5 μg/ml). Either PBS or several concentrations of Didox or Trimidox (25 μM
and 50 μM) was added to RPMI 1640 growth media supplemented with 10% fetal bovine serum, 50 μM 2-Mercaptoethanol and 1% penicillin
streptomycin. The plates were then incubated at 37°C and 5% CO2 for 24, 48, 72 or 96 hours, after which spectrophotometric quantification of
cell growth and viability was determined. The results shown represent data obtained in triplicate from two independent experiments. (A)
Treated with Didox (B) Treated with Trimidox. Values shown (mean ± SD) represent data obtained in triplicate from two independent
experiments. * indicate a significant difference compared to anti CD3ε stimulated. (p < 0.05, ANOVA + the Bonferroni test).
Figure 2 Cellular toxicity of Didox and Trimidox in T-cells from C57BL6 and B10.D2 mouse strains. Briefly, 1 × 105 cells per well were
seeded in 96 well culture plates in RPMI 1640 supplemented with 10% fetal bovine serum and 1% penicillin streptomycin and 2-
mercaptoethanol, containing PBS or concentrations of Didox or Trimidox from 25 μM- 100 μM. The cells were then incubated at 37°C and 5%
CO2 for 4 days. After this, percentage of viable cells of (A) Didox and (B) Trimidox was determined for each drug dose. * indicates a significant
difference compared to PBS treated (UT). (p < 0.05, ANOVA + the Bonferroni test; n = 3).
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We observed an even greater inhibition of cytokine
production by Trimidox following anti-CD3ε stimulation
of T-cell cultures in both B10.D2 and C57BL6 mice.
The production of IFN-g was below detectable levels in
both cell types at either 24 or 48 hours. The production
of IL-2 in both cell types was comparable to that of
unstimulated cells of the same strain; this pattern was
also true for IL-6 production.
We also examined the production of several Th2 type
cytokines IL-4, IL-13 and IL-10 (Figure 4). Normal con-
trol cell supernatants contained minimal levels of IL-4,
IL-13 and IL-10. Following stimulation with anti-CD3ε,
cultures rapidly produced increased levels of Th2 type
cytokines at 24 hours post stimulation that further
increased at 48 hours post stimulation. Treatment with
Trimidox, even at the lowest dose (25 μM), reduced the
levels of IL-4 and IL-10 to the lower detection limits.
Interestingly, Trimidox treatment in either B10.D2 or
C57BL6 mice reduced levels of IL-13 to levels compar-
able to normal controls (NC). Didox treatment demon-
strated a dose dependant decrease in cytokine levels for
IL-4, IL-10 and IL-13.
The effects of Didox and Trimidox on Allogeneic MLR
The following experiments were performed to analyze
the effects of Didox and Trimidox in the complex inter-
action of allo-recognition and activation of responder T-
cells to both major (Figure 5A) and minor (Figure 5B)
Figure 3 Inhibition of TH1 cytokine secretion by Didox and Trimidox. Briefly, 2 × 105 T-cells per well were purified and seeded in 96 well
sterile plates pre-coated with PBS or anti CD3ε antibodies (5 μg/ml). Either PBS or several concentrations of Didox or Trimidox (25 μM- 100 μM)
was added to RPMI 1640 growth media supplemented with 10% fetal bovine serum, 2-mercaptoethanol (50 μM) and 1% penicillin streptomycin.
The plates were then incubated at 37°C and 5% CO2 for 24 or 48 hours, after which the levels in pg/ml of IFN-g, IL-2 and IL-6 were determined
using the Searchlight multiplex assay system. (A) B10.D2 mice; (B) C57BL6 mice. NC: Normal control, AC: Activated control. The values shown
(mean ± SD) represent data obtained in triplicate from two independent experiments. * p < 0.05, ** p < 0.001 indicates a significant difference
compared to activated control (AC), ANOVA + the Bonferroni test; n = 3.
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mismatched antigens. In the first set of experiments,
C57BL6 lymphocytes were stimulated with irradiated
BALB/c stimulators. Didox and Trimidox were added at
25 μM, 50 μM and 100 μM following initiation of the
cultures. As shown in Figure 5A., untreated cultures
demonstrated an increase in T-cell proliferation. The
addition of Didox or Trimidox at either 25 μM or 50
μM caused 40-45% inhibition of proliferation. The addi-
tion of 100 μM of Didox or Trimidox caused a 75-80%
inhibition of proliferative responses. The second set of
experiments used T-cells from B10.D2 mice as the
responders and irradiated non-T-cells from BALB/c
mice as the stimulators. Figure 5B. shows the inhibition
of proliferative responses by both Didox and Trimidox
in a dose dependant manner. Here we show a 20-25%
inhibition by both drugs at 25 μM, a 45-50% inhibition
by both drugs at 50 μM, and a 70-75% inhibition by
both drugs at 100 μM.
Didox and Trimidox inhibit cytokine production during
the MLR
In an extension of the anti-CD3ε studies in which we
observed an inhibition of cytokine production, we per-
formed similar Searchlight multiplex analysis on 6 day
culture supernatants from either major or minor antigen
mismatched MLRs. Figure 6 shows the results for IFN-g,
TNF-a, IL-2, and IL-6 cytokine levels from cell culture
supernatants in response to minor and major antigen
Figure 4 Inhibition of TH2 cytokine secretion by Didox and Trimidox. The levels in pg/ml of IL-4, IL-13 and IL-10 (*p < 0.05, ** p < 0.001)
were determined using the Searchlight procedure. (A) B10.D2 mice; (B) C57BL6 mice. NC: Normal control, AC: Activated control. The values
shown (mean ± SD) represent data obtained in triplicate from two independent experiments. * p < 0.05, ** p < 0.001 indicates a significant
difference compared to activated control (AC), ANOVA + the Bonferroni test; n = 3.
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stimulation. The base line production of cytokines is
represented in each graph by the normal control (NC),
unstimulated responder cells and untreated activated
control (AC). The minor MHC antigen stimulated cul-
tures showed only a minimal increase in cytokine pro-
duction, ranging from only a 25% increase in IFN-g to a
250% increase in IL-2. In sharp contrast, however, the
major antigen stimulation resulted in a 78.4 fold
increase in IFN-g expression when compared to the nor-
mal control group (Figure 6). These data clearly demon-
strate the inflammatory effect of major MHC
mismatched antigens to stimulate a potent cytokine
response for all four cytokines shown. A similar trend in
the secretion of IL-2 was observed, with only a 2-fold
increase in response to minor antigens and > 6 fold
increase with the major MLR (Figure 6). An increase in
IL-6 production was seen in both the major MLR and
minor MLR when compared to the normal controls.
Treatment with Didox or Trimidox was able to inhibit
MLR induced cytokine production in a dose dependent
manner. Trimidox inhibited cytokine production to
background levels at a dose of 25 μM for IL-2, 50 μM
for IFN-g, 100 μM for TNF-a and 100 μM for IL-6. In
contrast, a higher dose of Didox (100 μM) was needed
to inhibit IFN-g and IL-2 production to levels compar-
able to NC.
As shown in Figure 7, major antigen mismatched
MLRs resulted in a rapid upregulation of the Th2
derived cytokines, IL-13, IL-4 and IL-10. In the minor
antigen MLRs, a significant increase was only detected
in the production of IL-4, which was quenched by the
lowest dose (25 μM) of either Didox or Trimidox. NC
(unstimulated responder cells) had minimal levels of
cytokine production. Didox inhibited cytokine produc-
tion in a dose dependant manner for IL-13, IL-10 and
IL-4, with the 100 μM dose of Didox inhibiting cytokine
levels comparable to that in NC. Trimidox inhibited
cytokine production more vigorously than Didox with a
dose of 25 μM inhibiting IL-10, IL-13, and IL-4 by
approximately 40%, 60% and 90% respectively. Levels of
cytokines were reduced to or below that of NC by treat-
ment with a 50 μM dose. Together, these data demon-
strate the ability of the ribonucleotide reductase
inhibitors, Didox and Trimidox, to act as inhibitors of
inflammatory responses by both inhibiting the prolifera-
tion of T-cells and the production of cytokines.
Discussion
In this study, we determined the effect of Didox and
Trimidox on the proliferative response of T-cells.
Although ribonucleotide reductase inhibitors, specifically
HU, have been used extensively to synergize the actions
of other compounds, such as the combination of HU
with didanosine in the treatment of HIV [14,15], recent
studies have identified other potential applications based
on their cytostatic properties [16]. The results of this
report demonstrate the ability of Didox and Trimidox to
function as cytostatic compounds by inhibiting T-cell
proliferation that occurs as a consequence of SCT or
solid organ transplantation. In addition, the experiments
presented here demonstrate that Didox and Trimidox
Figure 5 Inhibition of T-cell proliferation responses in MLRs by
Didox and Trimidox. (A) Major antigen mismatch: Briefly, 2 × 105
T-cells were purified from spleens C57BL6 mice (responder cells)
were mixed with 4 × 105 irradiated non T-cells (stimulator cells)
obtained from BALB/c mice (exposed to 3000 rads of g-radiation).
(B) Minor antigen mismatch: Briefly, 2 × 105 T-cells were purified
from spleens B10.D2 mice (responder cells) which were mixed with
4 × 105 non T-cells (stimulator cells) obtained from BALB/c and pre-
exposed to 3000 rads of g-radiation. Either PBS (untreated) or several
concentrations of Didox or Trimidox (25 μM- 100 μM) was added to
RPMI 1640 growth media supplemented with 10% fetal bovine
serum, 50 μM 2-Mercaptoethanol and 1% penicillin streptomycin.
The plates were then incubated at 37°C and 5% CO2 for 6 days,
after which spectrophotometric quantification of cell growth and
proliferation was determined. The results shown represent data
obtained in triplicate from two independent experiments. Values
shown represent the mean ± SD obtained in triplicate from two
independent experiments. * indicates a significant difference
compared to PBS treated (Untreated). (p < 0.05, ANOVA + the
Bonferroni test).
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inhibit the proliferation of not only T-cells following
anti-CD3ε stimulation, but also in MLRs. Previous stu-
dies have identified T-cell proliferation, cytokine secre-
tion, and the resulting increased expression of
chemokines as crucial events following solid organ or
stem cell transplant (SCT). By specifically targeting
these responses, these compounds have the potential to
limit graft rejection or graft-versus-host disease [17,18].
The process of graft rejection is a complicated yet well
orchestrated event; the precise mechanisms are still not
completely understood. It is known that T-cells alone
are not sufficient for graft rejection, that cytokines are
required and that rejection is driven by a Th1-type pat-
tern of immune activation [19], and as such, a switch to
a predominantly Th2-type pattern can be beneficial to
graft survival at the cost of increased opportunistic
infections.
Previous work has shown that IL-2, IL-6, TNF-a and
IFN-g secretion is associated with acute graft-versus-
host disease [20,21], whilst increased circulatory levels
of IL-6 have been associated with chronic graft-versus-
host disease [22]. More recently, Mohty review the clini-
cal significance of Th1 cytokines in both amplification
of donor responses and direct cytotoxicity [23]. Hoping
to alleviate these detrimental events, we demonstrate
here, the ability of these compounds to inhibit the secre-
tion of the crucial cytokines, IL-2, IL-6, TNF-a and
IFN-g thereby reducing the collateral damage caused by
the direct actions of these cytokines, whilst decreasing
the proliferative capacity of the T-cells. The differential
inhibition of cytokines and T-cell proliferation may be
an indication that the two compounds, Didox and Tri-
midox may actually be functioning by two distinct
mechanisms. The first as an inhibitor of ribonucleotide
Figure 6 Inhibition of IFN-g, IL-2, IL-6 and TNF-a cytokine release from MLRs by Didox and Trimidox. Major antigen mismatch (filled
square): Briefly, 2 × 105 T-cells were purified from spleens of C57BL6 mice (responder cells) which were mixed with 4 × 105 non T-cells
(stimulator cells) obtained from BALB/c mice and exposed to 3000 rads of g-radiation. Minor antigen mismatch (open square): Briefly, 2 × 105 T-
cells were purified from the spleens of B10.D2 mice (responder cells) which were mixed with 4 × 105 non T-cells (stimulator cells) obtained from
BALB/c mice and previously exposed to 3000 rads of g-radiation. Either PBS or several concentrations of Didox or Trimidox (25 μM- 100 μM) was
added to RPMI 1640 growth media supplemented with 10% fetal bovine serum, 2-mercaptoethanol (50 μM)and 1% penicillin streptomycin. The
plates were then incubated at 37C and 5% CO2 for 6 days, after which the levels of IFN-g, IL-2 and IL-6 were determined using the Searchlight
multiplex assay system. NC: Normal control, AC: Activated control. The results shown represent data obtained in triplicate from two independent
experiments (n = 3). * p < 0.05, ** p < 0.001 indicates a significant difference compared to activated control (AC), ANOVA + the Bonferroni test.
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reductase, with its effects resulting in a reduction of
T-cell proliferation; the second mechanism may be act-
ing at another level, directly reducing inflammatory
cytokine levels. Previous studies show that both Didox
and Trimidox directly inhibit NFB phosphorylation at
concentrations comparable to this study [24]. Therefore,
the second mechanism, inhibiting cytokine levels may
be a result of Didox and Trimidox inhibition of NFB.
The concept of using drugs to inhibit T-cell prolifera-
tion is not a new one; however, a major drawback of
this approach has been the concurrent inhibition in any
residual anti-tumor, or graft versus leukemia (GVL)
effect of lymphocytes that remain. The beneficial effects
of GVL responses have been well documented [25-28].
This GVL effect is one that is most notably seen in allo-
geneic as opposed to autologous bone marrow trans-
plants and is dependent on the genetic mismatch
between graft and recipient. However, in order for this
retained GVL effect to be effective, T-cells populations
must also be able to activate and proliferate in response
to antigen, whether it is allo-antigen (major or minor),
tumor-antigen, tumor-associated antigen or a combina-
tion of all three.
Recent publications have demonstrated certain ribonu-
cleotide reductase inhibitors function as virostatics
[8,29] and that this effect may be an additional benefit.
More recently, the immune modulatory effects of HU
have been postulated. Lori et al described the “predator-
prey” hypothesis [29] where the cytostatic effects of HU
would force T-lymphocytes into becoming quiescent,
thus becoming less prone to HIV infection. The overall
effect is fewer numbers of infected cells and reduced
viral loads and ultimately more effective control by host
immune responses. Benito et al [30] described the anti-
proliferative effects of HU on T-cells without diminish-
ing their cellular activation.
Figure 7 Inhibition of IL-13, IL-10 and IL-4 cytokine release from MLRs by Didox and Trimidox. The levels of IL-13, IL-10 and IL-4 were
determined using the Searchlight multiplex assay system from minor (open square) or major (filled square) mixed lymphocyte reactions. NC:
Normal control, AC: Activated control. The results shown represent data obtained in triplicate from two independent experiments (n = 3-6).
(*p < 0.05, ** p < 0.001 indicates a significant difference compared to activated control (AC), ANOVA + the Bonferroni test.
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In addition to Didox and Trimidox being considered
for use as anti-proliferative agents, current research has
indicated that they are also successful as anti-tumor
agents. Raje, et al [31] demonstrates that Didox specifi-
cally induces a caspase-dependant cytotoxicity in multi-
ple myeloma (MM) cells. They demonstrate that not
only does Didox induce apoptosis in MM cells, but that
this is accompanied by a down-regulation of several
other genes including bcl-2, bclx1, and XIAP as well as
a reduction in both expression and protein levels of M1
subunit of ribonucleotide reductase. They also demon-
strated a myeloma-specific down-regulation of RAD 51
homologue, an active gene in DNA repair. The authors
conclude that Didox acts on both DNA synthesis and
repair.
In contrast to studies using HU [32], Didox and Tri-
midox also inhibited the production of Th2 type cyto-
kines. These cytokines are known to suppress many
pro-inflammatory cytokines and chemokines. In the
transplant scenario, upregulation of these cytokines may
be important in the generation of humoral responses.
The differential inhibition of Th1 cytokines by HU
results in a net increase in Th2 type cytokines, thus
further lowering the immune response and increasing
the potential for opportunistic infections. Here we show
that Didox and Trimidox inhibit both Th1 and Th2
cytokines possibly leaving the Th1:Th2 balance intact
although at a reduced level. The in vivo implications of
these data are important due to many factors. The
secretion of IFN-g in the post transplant setting is
important in both direct cellular damage to host tissues
and also in the stimulation of cell mediated responses
[33]. Increased levels of IL-6 have also been found to be
a negative predictor of graft survival in numerous trans-
plant scenarios [34,35]. The widespread effect of IL-2 on
T-cell proliferation has been well documented and thus
serves as a target for many of the current immunosup-
pressive therapies. Our data implies that Didox and Tri-
midox can be important tools to inhibit the proliferation
of T-cells in the transplant setting by both inhibiting T-
cell proliferation and reducing detrimental cytokine
secretion. However, the question remains whether these
treatments would impair the normal host defenses
against microbial insults. Weinberg [32] suggests that
the action of ribonucleotide reductase inhibitors would
not impair immunological responses to opportunistic
pathogens as their actions are limited to stimulated lym-
phocytes and that unstimulated PBMCs are unaffected.
Finally, one of the major side effects of current ribo-
nucleotide reductase inhibitor treatment is the potential
for myelotoxicity, an unfavorable side effect post trans-
plant. These effects can be directly damaging to the
bone marrow by preventing the mobilization of stems
cells and thus affecting the self-renewal capacity of the
bone marrow as a whole. As such, this myelotoxicity
can persist for many years following cessation of treat-
ment further impairing future treatments. However, pre-
vious work has shown the improved antiviral effects of
Didox and Trimidox with a limited myelosuppressive
effects [10] compared to HU, which indicates that,
unlike HU, myelotoxicity would not be as problematic
when using Didox or Trimidox.
To summarize, allogeneic SCT results in the up regu-
lation of a plethora of chemokines, cytokines, and tran-
scription factors which culminate in the homing/
localization and emergence of host reactive T-cells
resulting in graft-versus-host disease in the recipient
[36,37]. These studies demonstrate that both Didox and
Trimidox, at doses achievable in vivo, have anti-prolif-
erative effects on T-cells in response to allo-antigens
and downregulate crucial cytokine secretion associated
with graft versus host disease. These findings indicate
that Didox and Trimidox act in a multifaceted manner,
and as such, would be suitable candidates for further
evaluation in animal models of solid organ transplant,
graft-versus-host disease and autoimmunity.
Abbreviations
IFN-g: interferon-gamma; MLR: mixed lymphocyte reaction; RRI:
ribonucleotide reductase inhibitor; CyA: cyclosporine A; GVHD: graft-versus-
host disease.
Acknowledgements
We are very grateful to Dr. Beth A. Garvy and Yajarayma Tang-Feldman for
their critical review of the manuscript and helpful discussions. This work
was supported by a National Institutes of Health grant: 1R15HD065605-01
(O.R.O.).
Author details
1Department of Clinical Sciences, University of Kentucky, Lexington, KY
40536, USA. 2Molecules for Health, Inc., Richmond, VA 23219, USA.
3Departments of Biological Sciences and Public Health Sciences, Clemson
University, Clemson, SC 29634, USA.
Authors’ contributions
MI participated in the design of the experiments, carried out the T-cell
isolation, T-cell proliferation, cytokine analysis and MLR and analysis of the
data. IE participated in the T-cell proliferation assays and statistical analysis.
MB participated in the T-cell proliferation assays. HE supplied the
compounds Trimidox and Didox and participated in the determination of
the in vitro dosing. VG assisted in drafting the manuscript. OO conceived
the study, directed its design and coordination and drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
HE is President and a shareholder of Molecules for Health (MFH) and
thereby has a financial interest in Didox or Trimidox therapeutic potential.
All other authors declare that they have no competing interests.
Received: 5 April 2010 Accepted: 18 August 2010
Published: 18 August 2010
References
1. Hong JC, Kahan BD: Immunosuppressive agents in organ transplantation:
past, present, and future. Seminars in nephrology 2000, 20:108-25.
2. Yarbro JW: Mechanism of action of hydroxyurea. Seminars in oncology
1992, 19:1-10.
Inayat et al. Journal of Inflammation 2010, 7:43
http://www.journal-inflammation.com/content/7/1/43
Page 10 of 11
3. Kennedy BJ: The evolution of hydroxyurea therapy in chronic
myelogenous leukemia. Seminars in oncology 1992, 19:21-6.
4. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P: Long-
term incidence of hematological evolution in three French prospective
studies of hydroxyurea and pipobroman in polycythemia vera and
essential thrombocythemia. Seminars in thrombosis and hemostasis 2006,
32:417-21.
5. Smith CH: Use of hydroxyurea in psoriasis. Clinical and experimental
dermatology 1999, 24:2-6.
6. Anderson N: Hydroxyurea therapy: improving the lives of patients with
sickle cell disease. Pediatric nursing 2006, 32:541-3.
7. Fathallah H, Atweh GF: Induction of fetal hemoglobin in the treatment of
sickle cell disease. Hematology/the Education Program of the American
Society of Hematology American Society of Hematology 2006:58-62.
8. Lori F, Foli A, Kelly LM, Lisziewicz J: Virostatics: a new class of anti-HIV
drugs. Current medicinal chemistry 2007, 14:233-41.
9. Mayhew C, Oakley O, Piper J, Hughes NK, Phillips J, Birch NJ, Elford HL,
Gallicchio VS: Effective use of ribonucleotide reductase inhibitors (Didox
and Trimidox) alone or in combination with didanosine (ddI) to
suppress disease progression and increase survival in murine acquired
immunodeficiency syndrome (MAIDS). Cell Mol Biol (Noisy-le-grand) 1997,
43:1019-29.
10. Mayhew CN, Sumpter R, Inayat M, Cibull M, Phillips JD, Elford HL,
Gallicchio VS: Combination of inhibitors of lymphocyte activation
(hydroxyurea, trimidox, and didox) and reverse transcriptase
(didanosine) suppresses development of murine retrovirus-induced
lymphoproliferative disease. Antiviral Res 2005, 65:13-22.
11. Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters GJ,
Szekeres T, Krupitza G: The ribonucleotide reductase inhibitor trimidox
induces c-myc and apoptosis of human ovarian carcinoma cells. Life
sciences 2000, 67:3131-42.
12. Kaul DK, Kollander R, Mahaseth H, Liu XD, Solovey A, Belcher J, Kelm RJ Jr,
Vercellotti GM, Hebbel RP: Robust vascular protective effect of
hydroxamic acid derivatives in a sickle mouse model of inflammation.
Microcirculation 2006, 13:489-97.
13. Balzarini J: Effect of antimetabolite drugs of nucleotide metabolism on
the anti-human immunodeficiency virus activity of nucleoside reverse
transcriptase inhibitors. Pharmacol Ther 2000, 87:175-87.
14. Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J: Hydroxyurea and
didanosine is a more potent combination than hydroxyurea and
zidovudine. Antiviral therapy 1997, 2:31-8.
15. Gao WY, Cara A, Gallo RC, Lori F: Low levels of deoxynucleotides in
peripheral blood lymphocytes: a strategy to inhibit human
immunodeficiency virus type 1 replication. Proceedings of the National
Academy of Sciences of the United States of America 1993, 90:8925-8.
16. Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J:
Optimal suppression of HIV replication by low-dose hydroxyurea
through the combination of antiviral and cytostatic (’virostatic’)
mechanisms. AIDS London, England 2005, 19:1173-81.
17. Perez-Simon JA, Sanchez-Abarca I, Diez-Campelo M, Caballero D, San
Miguel J: Chronic graft-versus-host disease: Pathogenesis and clinical
management. Drugs 2006, 66:1041-57.
18. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS: Leukocyte
migration and graft-versus-host disease. Blood 2005, 105:4191-9.
19. Kishimoto K, Furukawa K, Ashizuka S, Sawada T, Ayabe H: Profile of
cytokine production during the inhibition of acute xenograft rejection.
Surgery today 2000, 30:159-62.
20. Via CS, Finkelman FD: Critical role of interleukin-2 in the development of
acute graft-versus-host disease. Int Immunol 1993, 5:565-72.
21. Garside P, Reid S, Steel M, Mowat AM: Differential cytokine production
associated with distinct phases of murine graft-versus-host reaction.
Immunology 1994, 82:211-4.
22. De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu T, Gerard C,
Abramowicz D, Scheerlinck JP, De Baetselier P, Urbain J, et al: Preferential
activation of Th2 cells in chronic graft-versus-host reaction. J Immunol
1993, 150:361-6.
23. Mohty M, Gaugler B: Inflammatory cytokines and dendritic cells in acute
graft-versus-host disease after allogeneic stem cell transplantation.
Cytokine Growth Factor Rev 2008, 19:53-63.
24. Lee R, Beauparlant P, Elford H, Ponka P, Hiscott J: Selective inhibition of l
kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression
by novel antioxidant compounds. Virology 1997, 234:277-90.
25. Ito M, Shizuru JA: Graft-vs.-lymphoma effect in an allogeneic
hematopoietic stem cell transplantation model. Biol Blood Marrow
Transplant 1999, 5:357-68.
26. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET,
Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MR:
Donor T cell-derived TNF is required for graft-versus-host disease and
graft-versus-tumor activity after bone marrow transplantation. Blood
2003, 101:2440-5.
27. Yang YG, Sykes M: The role of interleukin-12 in preserving the graft-
versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.
Leukemia & lymphoma 1999, 33:409-20.
28. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED: Antileukemic
effect of chronic graft-versus-host disease: contribution to improved
survival after allogeneic marrow transplantation. The New England journal
of medicine 1981, 304:1529-33.
29. Lori F: Hydroxyurea and HIV: 5 years later–from antiviral to immune-
modulating effects. AIDS London, England 1999, 13:1433-42.
30. Benito JM, Lopez M, Lozano S, Ballesteros C, Gonzalez-Lahoz J, Soriano V:
Hydroxyurea exerts an anti-proliferative effect on T cells but has no
direct impact on cellular activation. Clin Exp Immunol 2007, 149:171-7.
31. Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S,
Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC:
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and
inhibits DNA repair in multiple myeloma cells. British journal of
haematology 2006, 135:52-61.
32. Weinberg A: In vitro hydroxyurea decreases Th1 cell-mediated immunity.
Clinical and diagnostic laboratory immunology 2001, 8:702-5.
33. Obara H, Nagasaki K, Hsieh CL, Ogura Y, Esquivel CO, Martinez OM,
Krams SM: IFN-gamma, produced by NK cells that infiltrate liver
allografts early after transplantation, links the innate and adaptive
immune responses. Am J Transplant 2005, 5:2094-103.
34. Ioannidou E, Kao D, Chang N, Burleson J, Dongari-Bagtzoglou A: Elevated
serum interleukin-6 (IL-6) in solid-organ transplant recipients is
positively associated with tissue destruction and IL-6 gene expression in
the periodontium. Journal of periodontology 2006, 77:1871-8.
35. Cho WH, Kim HT, Sohn CY, Park CH, Park SB, Kim HC: Significance of IL-2,
IL-2R, IL-6, and TNF-alpha as a diagnostic test of acute rejection after
renal transplantation. Transplantation proceedings 1998, 30:2967-9.
36. Briscoe DM, Alexander SI, Lichtman AH: Interactions between T
lymphocytes and endothelial cells in allograft rejection. Curr Opin
Immunol 1998, 10:525-31.
37. Lalor PF, Adams DH: Lymphocyte homing to allografts. Transplantation
2000, 70:1131-9.
doi:10.1186/1476-9255-7-43
Cite this article as: Inayat et al.: Inhibition of allogeneic inflammatory
responses by the Ribonucleotide Reductase Inhibitors, Didox and
Trimidox. Journal of Inflammation 2010 7:43.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Inayat et al. Journal of Inflammation 2010, 7:43
http://www.journal-inflammation.com/content/7/1/43
Page 11 of 11
